Cytoreductive treatment strategies for de novo metastatic prostate cancer
Nature Reviews Clinical Oncology, Published online: 11 November 2019; doi:10.1038/s41571-019-0284-3Systemic hormone therapies and chemotherapy are the cornerstones of treatment for patients with de novo metastatic prostate cancer, with a currently limited role for local treatments. Herein, the authors outline the pathobiological and immunological rationale for local cytoreductive treatment of the primary tumour and/or metastases in patients with this disease. They also review the preclinical and clinical evidence for the use of radical prostatectomy, prostate radiotherapy, minimally invasive ablative therapies, and metastasis-directed therapy (predominantly with stereotactic ablative radiotherapy) in this population.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Martin J. Connor Taimur T. Shah Gail Horan Charlotte L. Bevan Mathias Winkler Hashim U. Ahmed Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Chemotherapy | Hormones | Prostate Cancer | Prostatectomy